All In Biotech

Drug Trial Radar · NCT06681766

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Dec 6, 2024

Primary completion

Apr 27, 2025

Study completion Apr 27, 2025

Sponsor

Lead sponsor
Larimar Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).

Conditions

  • Friedreich Ataxia

Interventions

  • NomlabofuspDrug

    Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.

  • PlaceboDrug

    The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEsTime frame: Up to 72 days (including screening)
  2. Number of subjects with ISRsTime frame: Up to 37 days
  3. Change from baseline in electrocardiogram (ECG) parameter - heart rate (HR)Time frame: Baseline, Day 7
  4. Change from baseline in electrocardiogram (ECG) parameter - PR intervalTime frame: Baseline, Day 7
  5. Change from baseline in electrocardiogram (ECG) parameter - QRS complexTime frame: Baseline, Day 7
  6. Change from baseline in electrocardiogram (ECG) parameter - QT intervalTime frame: Baseline, Day 7
  7. Change from baseline in electrocardiogram (ECG) parameter - QTcF (Corrected QT Interval)Time frame: Baseline, Day 7
  8. Change from baseline in echocardiogram (ECHO) parameter - ejection fraction (EF)Time frame: Baseline, Day 7
  9. Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-diastolic volume (LV EDV)Time frame: Baseline, Day 7
  10. Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-systolic volume (LV ESV)Time frame: Baseline, Day 7
  11. Change from baseline in echocardiogram (ECHO) parameter - relative wall thickness (RWT)Time frame: Baseline, Day 7
  12. Change from baseline in echocardiogram (ECHO) parameter - left ventricular mass (LVM)Time frame: Baseline, Day 7
  13. Change from baseline in echocardiogram (ECHO) parameter - left ventricular posterior wall thicknessTime frame: Baseline, Day 7
  14. Change from baseline in echocardiogram (ECHO) parameter - septal wall thicknessTime frame: Baseline, Day 7
  15. Change from baseline in echocardiogram (ECHO) parameter - mitral valve inflow DopplerTime frame: Baseline, Day 7
  16. Change from baseline in echocardiogram (ECHO) parameter - tissue DopplerTime frame: Baseline, Day 7
  17. Change from baseline in clinical laboratory assessment - sodiumTime frame: Baseline, Day 7
  18. Change from baseline in clinical laboratory assessment - potassiumTime frame: Baseline, Day 7
  19. Change from baseline in clinical laboratory assessment - glucoseTime frame: Baseline, Day 7
  20. Change from baseline in clinical laboratory assessment - blood urea nitrogenTime frame: Baseline, Day 7
  21. Change from baseline in clinical laboratory assessment - creatinineTime frame: Baseline, Day 7
  22. Change from baseline in clinical laboratory assessment - calcium, chlorideTime frame: Baseline, Day 7
  23. Change from baseline in clinical laboratory assessment - phosphorusTime frame: Baseline, Day 7
  24. Change from baseline in clinical laboratory assessment - total proteinTime frame: Baseline, Day 7
  25. Change from baseline in clinical laboratory assessment - total CO2Time frame: Baseline, Day 7
  26. Change from baseline in clinical laboratory assessment - albuminTime frame: Baseline, Day 7
  27. Change from baseline in clinical laboratory assessment - ASTTime frame: Baseline, Day 7
  28. Change from baseline in clinical laboratory assessment - ALTTime frame: Baseline, Day 7
  29. Change from baseline in clinical laboratory assessment - GGTTime frame: Baseline, Day 7
  30. Change from baseline in clinical laboratory assessment - ALPTime frame: Baseline, Day 7
  31. Change from baseline in clinical laboratory assessment - total bilirubinTime frame: Baseline, Day 7
  32. Change from baseline in clinical laboratory assessment - uric acidTime frame: Baseline, Day 7
  33. Change from baseline in clinical laboratory assessment - HbA1cTime frame: Baseline, Day 7
  34. Change from baseline in clinical laboratory assessment - hemoglobinTime frame: Baseline, Day 7
  35. Change from baseline in clinical laboratory assessment - hematocritTime frame: Baseline, Day 7
  36. Change from baseline in clinical laboratory assessment - RBC countTime frame: Baseline, Day 7
  37. Change from baseline in clinical laboratory assessment - RDWTime frame: Baseline, Day 7
  38. Change from baseline in clinical laboratory assessment - MCVTime frame: Baseline, Day 7
  39. Change from baseline in clinical laboratory assessment - MCHTime frame: Baseline, Day 7
  40. Change from baseline in clinical laboratory assessment - platelet countTime frame: Baseline, Day 7
  41. Change from baseline in clinical laboratory assessment - WBC countTime frame: Baseline, Day 7
  42. Change from baseline in clinical laboratory assessment - ANCTime frame: Baseline, Day 7
  43. Change from baseline in clinical laboratory assessment - EosinophilsTime frame: Baseline, Day 7
  44. Change from baseline in clinical laboratory assessment - MonocytesTime frame: Baseline, Day 7
  45. Change from baseline in clinical laboratory assessment - BasophilsTime frame: Baseline, Day 7
  46. Change from baseline in clinical laboratory assessment - LymphocytesTime frame: Baseline, Day 7
  47. Change from baseline in clinical laboratory assessment - BandsTime frame: Baseline, Day 7
  48. Change from baseline in clinical laboratory assessment - NeutrophilsTime frame: Baseline, Day 7
  49. Change from baseline in clinical laboratory assessment - CholesterolTime frame: Baseline, Day 7
  50. Change from baseline in clinical laboratory assessment - HDL cholesterolTime frame: Baseline, Day 7
  51. Change from baseline in clinical laboratory assessment - LDL cholesterolTime frame: Baseline, Day 7
  52. Change from baseline in clinical laboratory assessment - TriglyceridesTime frame: Baseline, Day 7
  53. Change from baseline in clinical laboratory assessment - very low-density lipoprotein cholesterolTime frame: Baseline, Day 7
  54. Change from baseline in clinical laboratory assessment - pHTime frame: Baseline, Day 7
  55. Change from baseline in clinical laboratory assessment - proteinTime frame: Baseline, Day 7
  56. Change from baseline in clinical laboratory assessment - bloodTime frame: Baseline, Day 7
  57. Change from baseline in clinical laboratory assessment - ketonesTime frame: Baseline, Day 7
  58. Change from baseline in clinical laboratory assessment - bilirubinTime frame: Baseline, Day 7
  59. Change from baseline in clinical laboratory assessment - urobilinogenTime frame: Baseline, Day 7
  60. Change from baseline in clinical laboratory assessment - nitritesTime frame: Baseline, Day 7
  61. Change from baseline in clinical laboratory assessment - leukocyte esteraseTime frame: Baseline, Day 7
  62. Change from baseline in clinical laboratory assessment - colorTime frame: Baseline, Day 7
  63. Change from baseline in clinical laboratory assessment - specific gravityTime frame: Baseline, Day 7
  64. Change from baseline in pulse rateTime frame: Baseline, Day 7
  65. Number of subjects with abnormal physical examinationsTime frame: Up to 72 days (including screening)
  66. Number of subjects with suicidal ideation, suicidal behavior, and suicidal ideation or behavior based on the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 72 days (including screening)
  67. Number of subjects who discontinue treatment and/or studyTime frame: Up to 37 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Uncommon Cures

    Chevy Chase, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.